Beginners’ Portfolio: What Have Vodafone Group plc, GlaxoSmithKline plc And Barclays PLC Done For Our Blue-Chip Prospects?

How did blue-chip purchases of Vodafone Group plc (LON: VOD), GlaxoSmithKline plc (LON: GSK) and Barclays PLC (LON: BARC) pan out?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

This article is the latest in a series that aims to help novice investors with the stock market. To enjoy past articles in the series, please visit our full archive.

The Beginners’ Portfolio is a virtual portfolio, run as if based on real money with all costs, spreads and dividends accounted for. Transactions made for the portfolio are for educational purposes only and do not constitute advice to buy or sell.

When I started the Beginners’ Portfolio my intention was to go for a combination of blue-chip dividend-paying shares and growth shares, and the success so far has been mixed with both approaches. Today I’m going to look at the blue-chip portion of the portfolio, paying special attention to one share I’ve since sold and two I still keep.

Telecoms profit

I sold Vodafone (LSE: VOD) back in December 2013 at a price of 234p, mainly because I thought its undervaluation was out by then, and partly because voice revenues were falling and I didn’t see a clear forward strategy for the company. As it happened, the timing worked out pretty well, and the portfolio made a capital gain of £166.46 with dividends of £58.35 added to the pot — a very nice overall gain of 45% over a 19-month period, after accounting for all costs.

Since then the price has been erratic and today is a little higher at 244p, but I think I made the right decision at the time.

Pharma laggard

GlaxoSmithKline (LSE: GSK) has not worked out as well as I thought it would have by now since I bought it in June 2012. In fact, if I sold at today’s 1,409p level I’d realise a loss on the share price of 6.6% — although total dividends of £79.56 would swing that to a modest total 9.2% gain after costs.

I thought the prospects of a return to earnings growth in 2016 would have improved sentiment towards Glaxo by now, but until that happens I’m happy to hold and keep taking dividend yields of around 6%.

Banking on banking

As the banking sector returned to health, I decided I wanted one to help give us a balanced portfolio, and I went for Barclays (LSE: BARC) in February 2014. Since then we’ve enjoyed a 6.7% gain (after costs) from a share price rise to 282p, with £15.75 in dividends taking the total gain to 9.6%.

One of my big reasons for choosing Barclays was its recovering dividend. It only yielded 2.7% in 2014 but it was very well covered. And we have EPS growth of around 33% forecast for this year, followed by another 20% in 2016, which makes me think we’re still in early days of Barclays’ recovery — and it was a good time to get in.

Bottom line

How has the blue-chip portion of the portfolio performed overall? I couldn’t finish without mentioning the overall 18% loss I took when I dumped Tesco, eased a little by some dividends in the early days. BP has been pretty flat with a total return of 2.8%, Rio Tinto is disappointingly down 13%, again softened by decent dividends, BAE Systems is sitting pretty with a very nice 54% overall gain, and Aviva has given us an even better 74% gain so far.

The blue-chip portion of the portfolio is up 16% after considering the effects of all costs (including the cost of selling the whole lot today). For an average holding time of around a couple of years, that compares reasonably well to the 10% or so we’d have gained from a FTSE 100 tracker over a similar period.

Next time I’ll take a look at the portfolio’s growth stocks.

Alan Oscroft has no position in any shares mentioned. The Motley Fool UK has recommended Barclays and GlaxoSmithKline, and owns shares in Tesco. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Two white male workmen working on site at an oil rig
Dividend Shares

More oil wobbles as the BP share price dives 7% in a day!

The BP share price has been wildly volatile in 2026, bouncing around with each new move in the US-Iran war.…

Read more »

British bank notes and coins
Investing Articles

Meet the 9.6%-yielding income share that could keep growing its payout!

This income share yields close to 10% -- and has grown its dividend per share year after year for well…

Read more »

Fireworks display in the shape of willow at Newcastle, Co. Down , Northern Ireland at Halloween.
Investing Articles

When will Barclays shares hit £10?

Barclays shares were close to £1 not so long ago, but could they do the unthinkable and make it to…

Read more »

Picture of an easyJet plane taking off.
Investing Articles

easyJet shares have bounced back before. On a P/E ratio of 6, could they do it again?

Our writer thinks easyJet shares could turn out to be a terrific bargain from a long-term perspective. So is he…

Read more »

Stack of British pound coins falling on list of share prices
Investing Articles

Could National Grid shares offer me a dividend that won’t be hurt by inflation?

National Grid aims to inflation-proof its dividend per share with a policy of annual rises that match inflation. Is our…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Here’s what happened to £1,000 invested in the past 2 stock market crashes

History may not repeat itself, but our writer reckons there are lessons to be learned from what recent stock market…

Read more »

Young Caucasian woman at the street withdrawing money at the ATM
Investing Articles

Here’s how the HSBC share price reached an all-time high… and what might be next

HSBC’s record share price reflects a strong rebound in profits and investor confidence, but future gains may be bumpier from…

Read more »

UK coloured flags waving above large crowd on a stadium sport match.
Investing Articles

Investors tempted by beaten-down Diageo shares should mark 6 May on their calendars now

Diageo is a top British blue-chip but its shares have come under fire in recent years. Harvey Jones hopes investors…

Read more »